Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temelimab in Recent Onset Type 1 Diabetes
NCT03179423Phase 2Completed
- Sponsor
- GeNeuro
- Start
- Jun 2017
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing GNbAC1 with Placebo (2 arms). Primary endpoint: Safety and tolerability of GNbAC1 at 48 weeks. Started Jun 2017; status: completed.
02
Drugs
temelimab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03179423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03179423.